Demographics and outcomes of initial phase of COVID-19 medicines delivery units across 4 UK centers during peak B1. 1.529 Omicron epidemic: a service evaluation
…, A Qureshi, M Plowright, K Drury, J Gahir… - Open forum …, 2022 - academic.oup.com
Background COVID-19 medicines delivery units (CMDU) were established in late December
2021 to deliver early antiviral therapy to patients classified as at risk with the aim of …
2021 to deliver early antiviral therapy to patients classified as at risk with the aim of …
Implementation of an intervention bundle leads to quality improvement in ulcerative colitis endoscopy reporting
Background Accurate and detailed endoscopy reporting in ulcerative colitis (UC) is critical
for clinical decision‐making. High‐quality reporting involves inclusion of several criteria, …
for clinical decision‐making. High‐quality reporting involves inclusion of several criteria, …
Neutralising immunity to omicron sublineages BQ. 1.1, XBB, and XBB. 1.5 in healthy adults is boosted by bivalent BA. 1-containing mRNA vaccination and previous …
EJ Carr, MY Wu, J Gahir, R Harvey… - The Lancet Infectious …, 2023 - thelancet.com
During the autumn of 2022, both the US Centers for Disease Control and Prevention and
the UK’s Joint Committee on Vaccination and Immunisation recommended the targeted …
the UK’s Joint Committee on Vaccination and Immunisation recommended the targeted …
Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest London
…, D Snell, M Finadis, A Edwards, J Perez-Lloret, J Gahir… - The Lancet, 2023 - thelancet.com
An important component of the UK’s early response to the COVID-19 pandemic was increasing
SARS-CoV-2 testing capacity across the National Health Service (NHS). At the time, we …
SARS-CoV-2 testing capacity across the National Health Service (NHS). At the time, we …
[HTML][HTML] COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA. 1, BA. 2, BA. 4/5 or Delta associates with similar illness duration …
H Townsley, J Gahir, TW Russell, D Greenwood… - Plos one, 2024 - journals.plos.org
Background SARS-CoV-2 variant Omicron rapidly evolved over 2022, causing three waves
of infection due to sub-variants BA.1, BA.2 and BA.4/5. We sought to characterise symptoms …
of infection due to sub-variants BA.1, BA.2 and BA.4/5. We sought to characterise symptoms …
[HTML][HTML] SARS-CoV-2 mucosal neutralising immunity after vaccination
…, M Ragno, P Stevenson-Leggett, J Gahir… - The Lancet Infectious …, 2024 - thelancet.com
Mucosal vaccines that prevent SARS-CoV-2 infection might provide benefits beyond existing
intramuscularly administered vaccines: through enhanced individual-level protection …
intramuscularly administered vaccines: through enhanced individual-level protection …
Delayed healthcare seeking and prolonged illness in healthcare workers during the COVID-19 pandemic: a single-centre observational study
A de Wilton, E Kilich, Z Chaudhry, LCK Bell, J Gahir… - BMJ open, 2020 - bmjopen.bmj.com
Objectives To describe a cohort of self-isolating healthcare workers (HCWs) with presumed
COVID-19. Design A cross-sectional, single-centre study. Setting A large, teaching hospital …
COVID-19. Design A cross-sectional, single-centre study. Setting A large, teaching hospital …
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA. 1, BA. 2, BA. 5 or Delta associates with similar illness duration, symptom …
H Townsley, J Gahir, TW Russell, EJ Carr, M Dyke… - medRxiv, 2022 - medrxiv.org
Background SARS-CoV-2 variant Omicron rapidly evolved over 2022, causing three waves
of infection due to sub-variants BA.1, BA.2 and BA.4/5. We sought to characterise symptoms …
of infection due to sub-variants BA.1, BA.2 and BA.4/5. We sought to characterise symptoms …
28 Experiences of using Paxlovid to treat clinically extremely vulnerable non-hospitalised patients with COVID-19
J Gahir, J Saund, M Brown, J Harchowal… - Clinical Infection in …, 2022 - ncbi.nlm.nih.gov
Methods SARS-CoV-2 positive CEV patients were triaged between 10/02/22 and 21/03/22.
Those meeting national eligibility criteria were considered for Paxlovid.
Those meeting national eligibility criteria were considered for Paxlovid.
Demographics and Outcomes of COVID-19 Medicines Delivery Units Across 4 UK Centres During the Initial B1. 1.529 Omicron Epidemic: A Service Evaluation.
…, J Saund, A Qureshi, M Plowright, K Drury, J Gahir… - 2022 - papers.ssrn.com
Introduction: COVID-19 Medicine Delivery Units (CMDU) were established in late December
2021 to deliver early antiviral therapy to patients classified as at risk with the aim of …
2021 to deliver early antiviral therapy to patients classified as at risk with the aim of …
